Anti-CD38 monoclonal antibodies – a new drug class for treating myeloma

Published on

At the Myeloma 2015 meeting held in Boston, Massachusetts, Dr Joseph Mikhael (Mayo Clinic, Scottsdale, AZ) talks about the new class of drugs, the anti-CD38 monoclonal antibodies, that could represent the next significant advance in the treatment of myeloma.  

View more programs featuring

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on January 26, 2016